Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

329.89 -10.27 (-3.02%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

61 62 Next >

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move ↗

February 10, 2025

Via The Motley Fool

3 Fabulous Dividend Stocks to Buy in February ↗

February 09, 2025

Via The Motley Fool

Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For

February 09, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

Via StockStory

We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars ↗

February 07, 2025

Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also...

Via Stocktwits

Uber To $80? Here Are 10 Top Analyst Forecasts For Thursday ↗

February 06, 2025

Via Benzinga

Amgen Options Trading: A Deep Dive into Market Sentiment ↗

February 05, 2025

Via Benzinga

Earnings Summary: Amgen Q4 ↗

February 04, 2025

Via Benzinga

Amgen Beat Fourth-Quarter Expectations. So, Why Did Shares Tumble? ↗

February 04, 2025

In after-hours trades, Amgen stock fell around 2% following its fourth-quarter beat.

Via Investor's Business Daily

What's going on in today's session: S&P500 movers ↗

February 05, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday? ↗

February 05, 2025

Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data.

Via Benzinga

Analyst Expectations For Amgen's Future ↗

January 28, 2025

Via Benzinga

Stay informed with the top movers within the S&P500 index on Wednesday. ↗

February 05, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Why Amgen (AMGN) Stock Is Trading Up Today

February 05, 2025

Shares of biotech company Amgen (NASDAQ:AMGN) jumped 5.3% in the afternoon session after the company reported strong fourth-quarter results. Amgen exceeded analysts' revenue expectations this quarter,...

Via StockStory

Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead ↗

February 05, 2025

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Via Benzinga

Topics Earnings

Earnings Miss? Amgen’s Dividend Still a Bright Spot

February 05, 2025

Via MarketBeat

This Is What Whales Are Betting On Amgen ↗

January 27, 2025

Via Benzinga

Amgen (AMGN) Q4 2024 Earnings Call Transcript ↗

February 05, 2025

AMGN earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Amgen Surpasses Q4 Earnings Forecasts ↗

February 04, 2025

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Via The Motley Fool

Amgen’s (NASDAQ:AMGN) Q4 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations

February 04, 2025

Biotech company Amgen (NASDAQ:AMGN) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 10.9% year on year to $9.09 billion. The company’s full-year revenue guidance of...

Via StockStory

These Were the 5 Top-Performing Stocks in the Dow Jones Industrial Average in January 2025 ↗

February 04, 2025

Via The Motley Fool

Topics Stocks

Markets React To Softening Trade Tariff Policy ↗

February 04, 2025

Monday’s trading session resulted in slight negative closes across major indexes, but there’s good news here: whereas the Dow finished the trading day -122 points, it was -400 a half hour before this...

Via Talk Markets

Topics Stocks Stocks / Equities

US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday? ↗

February 04, 2025

U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.

Via Benzinga

Earnings Scheduled For February 4, 2025 ↗

February 04, 2025

Via Benzinga

The Dogs Of The Dow 2025 ↗

January 31, 2025

The Dogs of the Dow is an investing strategy well-known to retail and institutional investors.

Via Talk Markets

Topics Stocks Stocks / Equities

Friday's pre-market session: top gainers and losers in the S&P500 index ↗

January 31, 2025

Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.

Via Chartmill

These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024 ↗

January 25, 2025

Via The Motley Fool

Topics Stocks

Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results ↗

January 24, 2025

The Danish drug giant reported a 22% weight loss over 36 weeks.

Via Investor's Business Daily

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗

January 22, 2025

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Via Benzinga

Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025? ↗

January 21, 2025

Via The Motley Fool

Topics Stocks

January 17, 2025

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Via Benzinga

Topics Economy

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

61 62 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.